Vir downsizes by 12%, will close St. Louis and Portland sites in 2024 to save $40M+ annually

As Vir Biotechnology expands beyond infectious diseases, where it made a mark in Ebola and the early days of Covid, the biotech will downsize and close two of its US sites to save $40 million or more annually, it said after Wednesday’s closing bell.

The San Francisco-based biotech, which developed…
Click here to view original post

Advertisement — Advertise with Biotech Networks